XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.25.3

INVENTORY | 9 Months Ended
--- | ---
Sep. 30, 2025
Inventory Disclosure [Abstract] |
INVENTORY | NOTE 5 – INVENTORY Inventory consists of the following components: SCHEDULE OF INVENTORY
|  | September 30, 2025 |  |  | December 31, 2025 |
Raw materials |  | $ | 1,702 |  |  | $ | 391 |
Finished goods |  |  | 541 |  |  |  | 1,800 |
Total inventory |  | $ | 2,243 |  |  | $ | 2,191 |
Inventory write-down charged to the cost of sales amounted to $119 for the nine months ended September 30, 2025, respectively, to reduce inventory to its net realizable value and for any excess or obsolete inventory. The Company identified certain inaccuracies in its 510(k) application for the PainShield MD Plus product and on August 19, 2025 submitted a request to the U.S. Food and Drug Administration (FDA) to withdraw the clearance. While the Company is unaware of any safety issues related to the PainShield MD Plus product, it has decided to halt future sales. An appropriate inventory allowance was recorded for the impact of halt in sales in the amount of $119.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration